Psilocybin
Late-stage clinical developmentUnder investigation for Treatment-Resistant Depressive Disorder & Mental Disorders.
Also known as Psilocibina, Psilocybine, Psilocybinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Could Psilocybin Prevent Nerve Damage From Chemotherapy?
Effects of Psilocybin in Obsessive Compulsive Disorder
Compass posts positive psilocybin data; Solstice makes $225M debut
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder
Psychedelic-assisted therapy: An overview for the internist.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Scientific reports10
- Journal of psychopharmacology (Oxford, England)8
- JAMA psychiatry5
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology4
- Psychopharmacology4
- Acta psychiatrica Scandinavica3
- Nutt DJ10
- Erritzoe D9
- Carhart-Harris RL8
- Feilding A7
- Griffiths RR7
- Roseman L7
- Kaelen M6
- Barrett FS5
- Centre for Psychedelic Research6
- Imperial College London6
- Johns Hopkins University School of Medicine6
- The Beckley Foundation6
- University of Basel6
- Center for Psychedelic and Consciousness Research5
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 13 of the same disease areas as Psilocybin in the shared literature.
Studied across 4 of the same disease areas as Psilocybin in the shared literature.
Studied across 2 of the same disease areas as Psilocybin in the shared literature.
Studied across the same disease area as Psilocybin in the shared literature.
Studied across the same disease area as Psilocybin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials